Published in Health and Medicine Week, October 27th, 2003
Interferon beta is the first-line treatment for relapsing-remitting multiple sclerosis, but the drug can induce neutralizing antibodies against itself, which might reduce its effectiveness.
Per Soelberg Sorensen from Copenhagen University Hospital, Denmark, and colleagues measured neutralizing antibodies every year for up to 5 years among 541 patients with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health and Medicine Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.